Novel CDK9 Inhibitor Looks to Expand Options in MYC-Amplifie

Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.

Related Keywords

California , United States , American , Miguel Villalona Calero , Kronos Bio , National Cancer Institute , American Association For Cancer Research , Developmental Cancer Therapeutics Program , Early Phase Therapeutics Program , Medical Oncology , Therapeutics Research , American Association , Cancer Research , Accessed May , Patients With Relapsed Or Refractory Solid Tumors , Non Hodgkin Lymphoma , Kb 0742 , Nct04718675 , D , City Of Hope ,